A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma

O’Donnell, Elizabeth; P. Laubach, Jacob; J. Yee, Andrew; Chen, Tianqi; Ann Huff, Carol; G. Basile, Frank; M. Wade, Philip; E. Paba‐Prada, Claudia; M. Ghobrial, Irene; Schlossman, Robert; N. Burke, Jill; Harrington, Cynthia; J. Lively, Kathleen; Lyons, Hannah; C. Munshi, Nikhil; C. Anderson, Kenneth; Trippa, Lorenzo; G. Richardson, Paul; Raje, Noopur

doi:10.1111/bjh.15261

Public

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma

Published in British Journal of Haematology • May 8, 2018

Authors:

Elizabeth O’Donnell

Jacob P. Laubach

Andrew J. Yee

Abstract

Abstract We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant‐ineligible multiple myeloma ( MM ) patients. Our study evaluated modified lenalidomide‐bortezomib‐dexamethasone ( RVD lite) in this population and was administered over a 35‐day cycl...

Subject

Lenalidomide

Medicine

Bortezomib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!